Renal effects of levosimendan: a consensus report.

Cardiovasc Drugs Ther 2013 Dec;27(6):581-90

Department of Cardiology, Cumhuriyet University School of Medicine, Sivas, Turkey,

Renal dysfunction is common in clinical settings in which cardiac function is compromised such as heart failure, cardiac surgery or sepsis, and is associated with high morbidity and mortality. Levosimendan is a calcium sensitizer and potassium channel opener used in the treatment of acute heart failure. This review describes the effects of the inodilator levosimendan on renal function. A panel of 25 scientists and clinicians from 15 European countries (Austria, Finland, France, Hungary, Germany, Greece, Italy, Portugal, the Netherlands, Slovenia, Spain, Sweden, Turkey, the United Kingdom, and Ukraine) convened and reached a consensus on the current interpretation of the renal effects of levosimendan described both in non-clinical research and in clinical study reports. Most reports on the effect of levosimendan indicate an improvement of renal function in heart failure, sepsis and cardiac surgery settings. However, caution should be applied as study designs differed from randomized, controlled studies to uncontrolled ones. Importantly, in the largest HF study (REVIVE I and II) no significant changes in the renal function were detected. As it regards the mechanism of action, the opening of mitochondrial KATP channels by levosimendan is involved through a preconditioning effect. There is a strong rationale for randomized controlled trials seeking beneficial renal effects of levosimendan. As an example, a study is shortly to commence to assess the role of levosimendan for the prevention of acute organ dysfunction in sepsis (LeoPARDS).

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-013-6485-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830192PMC
December 2013
44 Reads
14 Citations
3.190 Impact Factor

Publication Analysis

Top Keywords

renal function
12
effects levosimendan
12
heart failure
12
renal effects
12
levosimendan
8
randomized controlled
8
cardiac surgery
8
renal
7
levosimendan indicate
4
reports levosimendan
4
indicate improvement
4
study reports
4
clinical study
4
improvement renal
4
reports reports
4
failure sepsis
4
applied study
4
study designs
4
designs differed
4
caution applied
4

References

(Supplied by CrossRef)

M Metra et al.
Eur Heart J 2012

S Kallel et al.
Nephrol Ther 2013

M Oppert et al.
Nephrol Dial Transplant 2008

HL Hillege et al.
Circulation 2006

HL Hillege et al.
Circulation 2000

Z Papp et al.
Int J Cardiol 2012

G Landoni et al.
J Cardiothorac Vasc Anesth 2010

MS Nieminen et al.
J Cardiovasc Pharmacol 2009

M Kivikko et al.
Circulation 2003

PS Pagel et al.
Br J Pharmacol 1996

V Faivre et al.
Anesthesiology 2005

Similar Publications